Robert Azelby - 27 Jan 2022 Form 4 Insider Report for Eliem Therapeutics, Inc. (CLYM)

Role
President & CEO, Director
Signature
/s/ Alan Hambelton, Attorney-in-Fact
Issuer symbol
CLYM
Transactions as of
27 Jan 2022
Net transactions value
$0
Form type
4
Filing time
31 Jan 2022, 16:13:59 UTC
Previous filing
09 Aug 2021
Next filing
02 Nov 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELYM Stock Option (Right to Buy) Award $0 +500,000 $0.000000 500,000 27 Jan 2022 Common Stock 500,000 $8.21 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 For so long as the Reporting Person continuously provides services to the Issuer, this option will vest with respect to the shares as follows: 1/48th of the shares will vest on each monthly anniversary of January 27, 2022.